Citadel Advisors
STOK icon

Citadel Advisors’s Stoke Therapeutics STOK Stock Holding History

Citadel Advisors’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-35,000
Closed -$1.14M – 14804
2026
Q1 		$1.14M Buy
35,000
+300
+0.9% +$9.84K ﹤0.01% 7363
2025
Q4 		$1.1M Buy
34,700
+18,800
+118% +$565K ﹤0.01% 7178
2025
Q3 		$374K Buy
+15,900
New +$272K ﹤0.01% 9833
2025
Q2 		– Sell
-2,900
Closed -$19.3K – 14979
2025
Q1 		$19.3K Sell
2,900
-100
-3% -$932 ﹤0.01% 13170
2024
Q4 		$33.1K Sell
3,000
-3,600
-55% -$44.2K ﹤0.01% 12778
2024
Q3 		$81.1K Sell
6,600
-4,700
-42% -$66.6K ﹤0.01% 11393
2024
Q2 		$153K Sell
11,300
-38,500
-77% -$520K ﹤0.01% 10324
2024
Q1 		$672K Buy
49,800
+48,900
+5,433% +$296K ﹤0.01% 7747
2023
Q4 		$4.73K Sell
900
-300
-25% -$1.28K ﹤0.01% 13487
2023
Q3 		$4.73K Sell
1,200
-9,200
-88% -$60.5K ﹤0.01% 13457
2023
Q2 		$111K Sell
10,400
-1,400
-12% -$14.9K ﹤0.01% 10779
2023
Q1 		$98.3K Sell
11,800
-3,400
-22% -$30.7K ﹤0.01% 11292
2022
Q4 		$140K Buy
+15,200
New +$158K ﹤0.01% 10715
2021
Q4 		– Sell
-13,200
Closed -$336K – 14722
2021
Q3 		$336K Sell
13,200
-600
-4% -$16.7K ﹤0.01% 10808
2021
Q2 		$465K Buy
13,800
+1,300
+10% +$46K ﹤0.01% 10211
2021
Q1 		$486K Sell
12,500
-2,600
-17% -$148K ﹤0.01% 9741
2020
Q4 		$935K Buy
15,100
+700
+5% +$32.1K ﹤0.01% 6936
2020
Q3 		$482K Buy
+14,400
New +$411K ﹤0.01% 7368

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors's STOK Position: Q2 2026 in Review

Citadel Advisors increased its Stoke Therapeutics (STOK) stake by 298% in Q2 2026, buying an estimated $11.8M and bringing the position to 489,301 shares worth $16M. The position accounts for ﹤0.01% of the portfolio, ranked #2878.

Citadel Advisors first reported a position in STOK in Q2 2019 and has held it in 23 quarters since. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Citadel Advisors held 489,301 shares of Stoke Therapeutics worth $16M as of Q2 2026.
  • Citadel Advisors bought 366,279 Stoke Therapeutics shares in Q2 2026, an estimated $11.8M.
  • Stoke Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2878 holding.
  • Citadel Advisors first reported a position in Stoke Therapeutics in Q2 2019 and has held it in 23 quarters since.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.